Cyclohexane

Cyclohexane

SCHEMBL1573965

C1CCCCC1.CCC(C)=O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.77
TDP1 Q9NUW8 4/20 0.77
FFAR3 O14843 2/20 0.53
TRPA1 O75762 1/20 0.41
LMNA P02545 3/20 0.36
TSHR P16473 3/20 0.35
SLC15A2 Q16348 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
SOAT1 P35610 1/20 0.33
THPO P40225 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclooctane SCHEMBL17142032 1.00 ALDH1A1 (0.77) ALDH1A1TDP1FFAR3TRPA1LMNA
Cyclohexane SCHEMBL6936130 0.96 ALDH1A1 (0.71) ALDH1A1TDP1FFAR3TRPA1LMNA
Butanone SCHEMBL1310 0.88
Butanone SCHEMBL1039820 0.88 ALDH1A1 (1.00) ALDH1A1TDP1FFAR3TRPA1LMNA
Butanone SCHEMBL8379087 0.88 ALDH1A1 (1.00) ALDH1A1TDP1FFAR3TRPA1LMNA
Butanone SCHEMBL1510153 0.88
Butanone SCHEMBL20557981 0.84
Butanone SCHEMBL21631022 0.84
Butanone SCHEMBL5386702 0.84
Butanone SCHEMBL22405658 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11414374-B2 Crystalline forms of vilanterol trifenatate and processes for their preparation HOVIONE SCIENTIA LIMITED (IE) 2022-08-16 US claimed
CN-114685566-A Benzene arsenic oxide crystal form I, crystal form II and crystal form III and preparation method thereof 江苏挪贝肽医药科技有限公司 2022-07-01 CN claimed
US-20200148626-A1 New Crystalline Forms of Vilanterol Trifenatate and Processes for Their Preparation HOVIONE SCIENTIA LIMITED (IE) 2020-05-14 US claimed
CN-108368316-B Composition, laminate, packaging material for battery case, and battery 三井化学株式会社 2024-07-16 CN disclosed
US-20240190815-A1 CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF SPRINGWORKS THERAPEUTICS, INC. 2024-06-13 US disclosed
CN-114729246-B Adhesive for electronic tag and electronic tag 三井化学株式会社 2024-05-28 CN disclosed
WO-2024085235-A1 METHOD FOR PRODUCING CYCLIC PEPTIDE CRYSTALS 中外製薬株式会社 2024-04-25 WO disclosed
US-11884610-B2 Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof SPRINGWORKS THERAPEUTICS, INC. (US) 2024-01-30 US disclosed
US-20230032403-A1 CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF SpringWorks Therapeutics Inc. (US) 2023-02-02 US disclosed
US-11414374-B2 Crystalline forms of vilanterol trifenatate and processes for their preparation HOVIONE SCIENTIA LIMITED (IE) 2022-08-16 US disclosed
CN-114867806-A Adhesive composition, heat-fusible member, and packaging material for secondary battery 东亚合成株式会社 2022-08-05 CN disclosed
US-5066883-A ELECTRON-EMITTING DEVICE WITH ELECTRON-EMITTING REGION INSULATED FROM ELECTRODES CANON KABUSHIKI KAISHA (JP) 1991-11-19 US disclosed
US-5023110-A Process for producing electron emission device CANON KABUSHIKI KAISHA (JP) 1991-06-11 US disclosed
US-4857619-A Fluorine containing polymer having a terminal ester group PPG INDUSTRIES, INC. (US) 1989-08-15 US disclosed
US-4770976-A Phenanthroimidazole compounds, their preparation, photopolymerizable coating and recording materials, and lithographic layers produced using these BASF AKTIENGESELLSCHAFT (DE) 1988-09-13 US disclosed
US-4649081-A FERROMAGNETIC POWDER; MODIFIED SILICON COMPOUND FUJI PHOTO FILM CO., LTD. (JP) 1987-03-10 US disclosed
US-4529563-A Surface treatment Fais, Robert G. (US) 1985-07-16 US disclosed
US-4410565-A THERMOPLASTIC RESIN, FERROMAGNETIC METAL FUJI PHOTO FILM CO., LTD. (JP) 1983-10-18 US disclosed
US-4089993-A Method of forming a metallic thin film by electroless plating on a vinylidene chloride undercoat FUJI PHOTO FILM CO., LTD. (JA) 1978-05-16 US disclosed
US-3962276-A ENZYME INHIBITORS ELI LILLY AND COMPANY (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884610-B2 Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof NRAS, BRAF, KSR2 ALDH1A1 3605/4885TDP1 2584/4885FFAR3 556/4885
US-20230032403-A1 CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF NRAS, BRAF, KSR2 ALDH1A1 3360/4885TDP1 2177/4885FFAR3 497/4885
US-20240190815-A1 CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF NRAS, BRAF, KSR2 ALDH1A1 3466/4885TDP1 2271/4885FFAR3 521/4885
US-11414374-B2 Crystalline forms of vilanterol trifenatate and processes for their preparation PRKCD, PRKCQ, CYP24A1 ALDH1A1 2905/4885TDP1 824/4885FFAR3 392/4885
US-20200148626-A1 New Crystalline Forms of Vilanterol Trifenatate and Processes for Their Preparation PRKCD, PRKCQ, PDE12 ALDH1A1 3195/4885TDP1 728/4885FFAR3 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.